Programming Implantable Cardioverter Defibrillators in Patients With Primary Prevention Indication (PROVIDE)

Abbott

Status: Completed

Conditions: Shock

Treatments: Device: ICD/ CRT-D

Study type: Observational

Funder types: Industry

Identifiers

NCT00743522

448

Details and patient eligibility

About

Although shock therapy is effective in terminating ventricular tachycardia (VT), it can be painful to the patient and repetitive shocks can decrease a patient's quality of life. Previous studies have suggested that one or more sets of aggressive device parameter settings may reduce the total number of shocks in primary prevention patients. In addition to shock therapies, antitachycardia pacing (ATP) is also available in ICDs to treat VT. The PROVIDE trial aims to prospectively study the effect of high detection rates, prolonged detection intervals, aggressive SVT discriminators, and extensive ATP therapy in prolonging the time to first shock in primary prevention patients.

Enrollment: 1,670 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Primary Prevention indication for ICD/ CRT-D

Exclusion criteria

• No prior documented history of spontaneous VT/VF

Trial design

1,670 participants in 2 patient groups

Control

Description:

PROVE Trial settings

Treatment:

Device: ICD/ CRT-D

Experimental

Description:

Pre-selected settings

Treatment:

Device: ICD/ CRT-D